You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物科技服務(08037.HK)淋巴瘤新藥獲國家藥監批准臨床試驗
阿思達克 01-22 09:37
中國生物科技服務(08037.HK)公布,附屬上海隆耀於1月21日,收到國家藥品監督管理局批准上海隆耀名稱為LY007的細胞注射液臨床試驗之批准通知書,註冊分類為I類新藥。

LY007細胞注射液是一種嵌合抗原受體T細胞(CAR-T)注射液,主要用於治療復發難治的CD20陽性的B細胞型非霍奇金淋巴瘤,包括瀰漫大B細胞淋巴瘤和轉化型濾泡性淋巴瘤。

LY007細胞注射液由上海隆耀自主研發,採用了隆耀擁有自主知識產權的OX40共刺激信號設計。實驗證明該設計在保障安全性的前提下,提高了產品的功效。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account